This is a working overview of prothymosin alpha, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-09-11. Anything still debated is marked as such rather than presented as settled.
Several factors accelerate degradation: alkaline pH, elevated temperature, exposure to oxidants, and the presence of residual moisture. Deamidation of asparagine residues and oxidation of methionine are the most commonly reported degradation routes. Because the peptide lacks disulfide bonds, it does not undergo the thiol-related aggregation seen in some other biologics, but physical aggregation can still occur at high concentration. Stability data are product-specific, and extrapolating shelf life between formulations is not reliable.
Lyophilized thymosin alpha-1 is generally stored at or below minus twenty degrees Celsius, protected from moisture and light. Short-term handling at ambient temperature is possible for dry powder, but reconstituted solutions degrade faster and are usually kept at two to eight degrees Celsius with a defined expiry of days rather than weeks. Repeated freeze-thaw cycles should be avoided because they promote aggregation and loss of potency. Exact limits depend on the formulation and should follow the supplier's documentation.
Recommended storage for the dry powder is a freezer near minus twenty degrees Celsius, kept desiccated and away from light. Once dissolved, the peptide is less stable and is usually held at two to eight degrees Celsius for short intervals or frozen for longer storage. Stability studies focus on the acetylated terminus and the disulfide linkage because those features define the intact molecule. Common degradation routes include cysteine oxidation, deamidation of asparagine or glutamine side chains, and slow formation of higher-molecular-weight species.
Identity and purity are usually checked by reverse-phase high-performance liquid chromatography, which separates the intact chain from truncated products, together with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion and amino acid analysis add sequence-level evidence. Release testing also covers water content, residual solvents, and counter-ions, all of which influence measured mass and stability. Related-peptide limits are commonly expressed as a percentage of total peak area, with individual unspecified impurities held below a lower threshold.
| Property | Value | Notes |
|---|---|---|
| Storage temperature, powder | -20 °C or lower | Protect from light and moisture |
| Storage temperature, reconstituted | 2-8 °C | Use within days |
| Purity testing | Reversed-phase HPLC | Separates truncation products |
| Mass confirmation | Mass spectrometry | Detects deamidation and oxidation |
| Common salt forms | Acetate or trifluoroacetate | Affects solubility and weighing |
Like most short peptides, thymosin alpha-1 is susceptible to hydrolysis under strongly acidic or basic conditions and to oxidation when exposed to air over long periods. The acetylated amino terminus blocks one common degradation route, which contributes to the molecule's relative robustness in solution. Lyophilized material generally retains potency for extended periods when kept cold and dry. Once reconstituted, aqueous solutions are less stable and are typically used within a defined window rather than held indefinitely at ambient temperature.
Routine handling calls for storage of the lyophilized powder at refrigerated temperatures, away from light, in a sealed container. Working solutions are often prepared in sterile water or buffer and kept cold between uses. Repeated freeze-thaw cycles are generally avoided because they can promote aggregation and loss of material. Laboratories usually record lot number, reconstitution date, and storage conditions so that any change in behavior can be traced to a specific preparation.
The compound has been investigated as an adjunct in chronic viral hepatitis and as a vaccine adjuvant, with results that vary by study design and population. Regulators in some countries have approved a synthetic form for specific indications, while other agencies have not. Whether the peptide produces consistent clinical benefit across diverse patient groups is still an open question, and many trials have been small. Its status is therefore best described as investigational in many contexts and established only narrowly.
The name itself causes confusion, because several unrelated thymic peptides share the thymosin label. Thymosin beta-4, for example, is a different molecule with different functions. Naming conventions in the literature also mix descriptive research terms with assigned nonproprietary names, so a reader should confirm which entity a given paper addresses. Clarifying that point is usually the first step in interpreting any claim about this peptide.
Thymosin alpha-1 is a short peptide of 28 amino acid residues first described in the 1970s as a component of thymic extracts. Its N-terminal residue carries an acetyl group, and the sequence is highly conserved across mammalian species. The peptide is not encoded as a standalone gene product; it is released by proteolytic cleavage from the N-terminus of prothymosin alpha, a larger acidic nuclear protein. That precursor relationship places it within a broader family of thymic and immune-associated peptides that have been studied for decades.
Thymosin alpha 1 is a 28-amino-acid peptide first isolated from thymosin fraction 5, a bovine thymic extract. Its sequence begins with an acetylated serine residue and carries a high proportion of acidic residues, so the molecule has a net negative charge near neutral pH. Despite the shared name, it is unrelated in sequence to the thymosin beta family. Synthetic material prepared by solid-phase peptide synthesis is identical in sequence to the natural peptide.
Several names appear in the literature for this peptide, including thymalfasin and the abbreviation T-alpha-1. Naming conventions differ among research articles, regulatory documents, and supplier catalogs, which complicates literature searches. Both synthetic and recombinant production routes yield a peptide with the same 28-residue sequence as the thymic isolate. Because the thymosin label also covers unrelated peptides, sources should be compared by sequence rather than by name alone.
The lyophilized peptide is generally stable for extended periods when kept cold and dry. Once dissolved, aqueous solutions are less stable; hydrolysis, oxidation, and aggregation can degrade the material. Storage at -20 °C or lower slows these processes. Repeated freeze-thaw cycles are best avoided because they can promote aggregation. The exact shelf life depends on formulation, pH, and concentration, so stability studies are typically performed for each specific product.
Quality control for thymosin alpha-1 focuses on identity, purity, and potency. Identity is confirmed by mass spectrometry and amino acid analysis, while purity is assessed by chromatography with limits on related substances and residual solvents. Potency assays may use cell-based immune readouts, but these are not standardized across laboratories. Regulatory status differs by jurisdiction; no product is approved in the United States for clinical use, whereas some other countries register injectable forms for specific indications.
Females are more aggressive than males during the courtship period, often fighting for access to mates, with fights among females accounting for more than half the aggressive interactions during this period. If females court a male that already has a partner, the incumbent female will try to repel the competitor, usually by chasing and kicking. These interactions can be prolonged, lasting up to five hours, especially when the male being fought over is single and neither female has the advantage of incumbency. In these cases, the females typically intensify their calls and displays. The sperm from a mating is stored by the female and can suffice to fertilise about six eggs. The pair mate every day or two, and every second or third day the female lays one of a clutch of five to fifteen very large, thick-shelled, green eggs. The shell is around 1 mm (0.04 in) thick, but rather thinner in northern regions according to indigenous Australians. The shell is substantially composed of calcite, and its δ13C is a function of the emu's diet. The eggs are on average 13 cm × 9 cm (5.1 in × 3.5 in) and weigh between 450 and 650 g (1.0 and 1.4 lb). The maternal investment in the egg is considerable, and the proportion of yolk to albumen, at about 50%, is greater than would be predicted for a precocial egg of this size. This probably relates to the long incubation period which means the developing chick must consume greater resources before hatching. The first verified occurrence of genetically identical avian twins was demonstrated in the emu. The egg surface is granulated and pale green.
== Former chains == A&W Restaurants - defunct in 2004 Burger Machine – now a food stall chain Cindy's - established Tarlac 1972, fastfood chain defunct by 2000s Go Nuts Donuts - defunct in 2020 IHOP - introduced 2014, local branches closed in 2022 Manong Pepe's - Jollibee Food Corporation venture into low cost carinderia style fast food. First store opened in 2007 and all stores closed down in 2011 Teddy's Bigger Burgers
The collapse of birthrates among blacks and (non-white) Hispanics, down 50%, was largely responsible for this development. However, their birthrates remained, on average, twice as high as those of their white counterparts. The birth rates of teenage Asians and Pacific Islanders were even lower, about half that of whites. In a 2014 paper, economists Melissa S. Kearney and Phillip B. Levine howed that popular TV programs depicting the reality of teenage parenthood, such as MTV's 16 and Pregnant and its Teen Mom sequels, have played a significant role in the reduction of teenage childbearing. Researchers from the Guttmacher Institute showed that the fall in teenage birthrates is likely not due to terminated pregnancies. The number of abortions remained the same or decreased in all U.S. states except for Vermont. This contradicts the historically negative correlation between birthrates and abortions. Modern youths also have better access to contraception than did their predecessors when they were at the same age. A CDC analysis found that the rates of teens using a long-acting and reversible method of contraception, such as an intrauterine device (IUD), jumped from 0.4% in 2005 to 7.1% in 2013. The teen birthrate continues to fall in the late 2010s, down to 17.4 births per 1000 in 2018. In 2022, it fell to 13.5, the lowest on record.
=== Data entry === When an electronic CRF is in use, data entry is carried out at the investigative site where the clinical trial is conducted by site staff who have been granted appropriate access to do so. When using a paper CRF the pages are entered by data entry operators. Best practice is for a first pass data entry to be completed followed by a second pass or verification step by an independent operator. Any discrepancies between the first and second pass may be resolved such that the data entered is a true reflection of that recorded on the CRF. Where the operator is unable to read the entry the clinical data manager should be notified so that the entry may be clarified with the person who completed the CRF.
Sources: en.wikipedia.org
The therapeutic dosage varies according to the patient's age or clinical condition, but for all treatments with sertraline, it is recommended to start with lower dosages (25 to 50 mg/daily) and adjust according to the patient's therapeutic response, with a maximum maintenance dose of up to 200 mg per day.
A zoster vaccine is a vaccine that reduces the incidence of herpes zoster (a.k.a. shingles), a disease caused by reactivation of the varicella zoster virus, which is also responsible for chickenpox. Shingles provokes a painful rash with blisters and can be followed by chronic pain (postherpetic neuralgia) and other complications. Older people are more often affected, as are people with weakened immune systems (immunosuppression). Both shingles and postherpetic neuralgia can be prevented by vaccination. Two zoster vaccines have been approved for use in people over 50 years old. Shingrix (GSK) is a recombinant subunit vaccine that has been used in many countries since 2017. Zostavax (Merck), in use since 2006, is an attenuated vaccine which consists of a larger-than-normal dose of varicella vaccine. Unlike Shingrix, Zostavax is not suitable for people with immunosuppression or diseases that affect the immune system. Zostavax was discontinued in the United States in November 2020. Shingrix appears to prevent more cases of shingles than Zostavax, although side effects seem to be more frequent. Varicella vaccine is used to prevent diseases caused by the same virus.
Evidence from systematic reviews suggests that interventions such as farm biosecurity and water, sanitation, and hygiene (WASH) practices may reduce antimicrobial use and contribute to limiting the development and spread of resistance.
Sources: en.wikipedia.org
Dry lyophilized powder tolerates short ambient exposure during handling and shipping. Long-term room-temperature storage is not recommended because moisture uptake and slow degradation can occur over months. Storage at minus twenty degrees Celsius is the common practice for extended periods.
Typical entries list appearance, identity by mass spectrometry, purity by chromatography, water or moisture content, and residual counter-ion. Some certificates also report microbial limits and endotoxin for materials intended for laboratory use. The reported methods and acceptance ranges vary between suppliers.
The peptide is often supplied as an acetate or trifluoroacetate salt, and the counter-ion affects solubility, weight-per-mole calculations, and compatibility with cell assays. Trifluoroacetate can be undesirable in some biological experiments. Knowing the salt form is necessary for accurate concentration determination.
Reconstituted solutions are typically kept refrigerated at two to eight degrees Celsius when used within a short window, or frozen in aliquots for longer periods. Repeated freeze-thaw cycles are avoided because they can reduce recovery of intact peptide.